Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma
| Autor: | Yagi, Yu, Kanemasa, Yusuke, Ohigashi, An, Morita, Yuka, Tamura, Taichi, Nakamura, Shohei, Otsuka, Yuki, Kishida, Yuya, Kageyama, Akihiko, Shimizuguchi, Takuya, Toya, Takashi, Shimizu, Hiroaki, Najima, Yuho, Kobayashi, Takeshi, Haraguchi, Kyoko, Doki, Noriko, Okuyama, Yoshiki, Omuro, Yasushi, Shimoyama, Tatsu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 0025-7974 |
| Popis: | Rationale: Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality risk associated with immune effector cell-associated neurotoxicity syndrome and pseudoprogression, patients with central nervous system (CNS) involvement are less likely to receive CAR T-cell therapy. Patients concerns: We report a case of a 61-year-old, male patient with intravascular large B-cell lymphoma who suffered a CNS relapse after standard chemotherapy. Diagnosis: A diagnosis of intravascular large B-cell lymphoma with CNS involvement was made. Interventions: We treated the patient using CAR T-cell therapy following a conditioning regimen consisting of thiotepa and busulfan and autologous stem cell transplantation. Although he experienced grade 1 cytokine release syndrome, no other serious adverse events, such as immune effector cell-associated neurotoxicity syndrome or pseudoprogression, were observed. Outcomes: The patient achieved complete remission after the CAR T-cell infusion. Lessons: CAR T-cell therapy following autologous stem cell transplantation is a viable option for relapsed/refractory lymphoma with CNS infiltration. Further clinical studies are warranted to verify its safety and efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|